{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:22:40Z","timestamp":1791411760884,"version":"4.3.3"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5\u20136, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20\u201321, 2025 (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.cvot.org\" ext-link-type=\"uri\">http:\/\/www.cvot.org<\/jats:ext-link>).<\/jats:p>","DOI":"10.1186\/s12933-025-02700-0","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:32:23Z","timestamp":1746210743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes"],"prefix":"10.1186","volume":"24","author":[{"given":"Oliver","family":"Schnell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Almandoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Barnard-Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Bl\u00fcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doina","family":"Catrinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Ceriello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin M.","family":"Dayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Del Prato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Fern\u00e1ndez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fioretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Forst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James R.","family":"Gavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Giorgino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Henrik","family":"Groop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor A.","family":"Harsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiddo J. L.","family":"Heerspink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lutz","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Jadoul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Kanumilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Landmesser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Macieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Mankovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaus","family":"Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Milenkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othmar","family":"Moser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"M\u00fcller-Wieland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipesh C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F. H.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Raheli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Ryd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schaeffner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Wendy","family":"Spearman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alin","family":"Stirban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Topsever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Standl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"key":"2700_CR1","unstructured":"FDA. Guidance for industry diabetes mellitus\u2014evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes\u2014guidance document. 2008."},{"key":"2700_CR2","unstructured":"(FDA) USFaDA. Type 2 diabetes mellitus: evaluating the safety of new drugs for improving glycemic control guidance for industry (Draft) 2020 [Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/type-2-diabetes-mellitus-evaluating-safety-new-drugs-improving-glycemic-control-guidance-industry."},{"key":"2700_CR3","doi-asserted-by":"crossref","unstructured":"(NCD-RisC) NRFC. Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet 2024; 404(10467): 2077\u201393.","DOI":"10.1016\/S0140-6736(24)02317-1"},{"key":"2700_CR4","unstructured":"Federation WO. Prevalence of obesity 2024 [Available from: https:\/\/www.worldobesity.org\/about\/about-obesity\/prevalence-of-obesity."},{"issue":"3","key":"2700_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.330","volume":"5","author":"M Bl\u00fcher","year":"2022","unstructured":"Bl\u00fcher M, Ceriello A, Davies M, Rodbard H, Sattar N, Schnell O, et al. Managing weight and glycaemic targets in people with type 2 diabetes-how far have we come? Endocrinol Diabetes Metab. 2022;5(3): e00330.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"2700_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229716","volume":"15","author":"S Gupta","year":"2020","unstructured":"Gupta S, Bansal S. Does a rise in BMI cause an increased risk of diabetes?: Evidence from India. PLoS ONE. 2020;15(4): e0229716.","journal-title":"PLoS ONE"},{"issue":"1","key":"2700_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","volume":"17","author":"TR Einarson","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007\u20132017. Cardiovasc Diabetol. 2018;17(1):83.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1614362","volume":"377","author":"A Afshin","year":"2017","unstructured":"Afshin A, Forouzanfar MH, Reitsma MB, Sur P, Estep K, Lee A, et al. Health effects of overweight and obesity in 195 countries over 25 years. N Engl J Med. 2017;377(1):13\u201327.","journal-title":"N Engl J Med"},{"issue":"12","key":"2700_CR9","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol CJASN. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"issue":"1","key":"2700_CR10","first-page":"S1","volume":"44","author":"American Diabetes Association","year":"2021","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142021. Diabetes Care. 2021;44(1):S1\u2013232.","journal-title":"Diabetes Care"},{"issue":"4","key":"2700_CR11","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s13679-024-00583-y","volume":"13","author":"D Kounatidis","year":"2024","unstructured":"Kounatidis D, Vallianou NG, Stratigou T, Voukali M, Karampela I, Dalamaga M. The kidney in obesity: current evidence perspectives and controversies. Curr Obes Rep. 2024;13(4):680\u2013702.","journal-title":"Curr Obes Rep"},{"issue":"5","key":"2700_CR12","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1002\/ejhf.1170","volume":"20","author":"PM Seferovi\u0107","year":"2018","unstructured":"Seferovi\u0107 PM, Petrie MC, Filippatos GS, Anker SD, Rosano G, Bauersachs J, et al. Type 2 diabetes mellitus and heart failure: a position statement from the heart failure association of the European society of cardiology. Eur J Heart Fail. 2018;20(5):853\u201372.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"2700_CR13","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.3390\/ijms25084397","volume":"25","author":"P Vidal-Cevallos","year":"2024","unstructured":"Vidal-Cevallos P, Sorroza-Mart\u00ednez AP, Ch\u00e1vez-Tapia NC, Uribe M, Montalvo-Jav\u00e9 EE, Nu\u00f1o-L\u00e1mbarri N. The relationship between pathogenesis and possible treatments for the MASLD-cirrhosis spectrum. Int J Mol Sci. 2024;25(8):4397.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2700_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jacc.2016.11.069","volume":"69","author":"S Javaheri","year":"2017","unstructured":"Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017;69(7):841\u201358.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"2700_CR15","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S2213-2600(19)30198-5","volume":"7","author":"AV Benjafield","year":"2019","unstructured":"Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip MSM, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis. Lancet Respir Med. 2019;7(8):687\u201398.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2700_CR16","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.3390\/ijms25031882","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran P, Weiskirchen R. The role of obesity in type 2 diabetes mellitus-an overview. Int J Mol Sci. 2024;25(3):1882.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2700_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD M\u00fcller","year":"2022","unstructured":"M\u00fcller TD, Bl\u00fcher M, Tsch\u00f6p MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201\u201323.","journal-title":"Nat Rev Drug Discov"},{"issue":"14","key":"2700_CR18","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"14","key":"2700_CR19","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"3","key":"2700_CR20","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"1","key":"2700_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69\u201379.","journal-title":"JAMA"},{"issue":"12","key":"2700_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1001\/jama.2019.13772","volume":"322","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155\u201366.","journal-title":"JAMA"},{"issue":"7","key":"2700_CR23","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"4","key":"2700_CR24","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"2700_CR25","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328.","journal-title":"N Engl J Med"},{"issue":"15","key":"2700_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425\u201335.","journal-title":"N Engl J Med"},{"issue":"2","key":"2700_CR27","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129\u201339.","journal-title":"N Engl J Med"},{"issue":"23","key":"2700_CR28","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"2700_CR29","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"2700_CR30","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"13","key":"2700_CR31","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228\u201339.","journal-title":"N Engl J Med"},{"issue":"10157","key":"2700_CR32","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519\u201329.","journal-title":"Lancet"},{"issue":"10","key":"2700_CR33","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385(10):896\u2013907.","journal-title":"N Engl J Med"},{"issue":"24","key":"2700_CR34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"24","key":"2700_CR35","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363.","journal-title":"N Engl J Med"},{"issue":"21","key":"2700_CR36","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"15","key":"2700_CR37","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324.","journal-title":"N Engl J Med"},{"issue":"2","key":"2700_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117\u201328.","journal-title":"N Engl J Med"},{"issue":"16","key":"2700_CR39","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"2700_CR40","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"issue":"2","key":"2700_CR41","doi-asserted-by":"publisher","first-page":"2300286","DOI":"10.1056\/EVIDoa2300286","volume":"3","author":"S James","year":"2024","unstructured":"James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, Andersen K, Austin D, Arefalk G, Carrick D, Hofmann R. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2024;3(2):2300286.","journal-title":"NEJM Evid"},{"issue":"12","key":"2700_CR42","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069\u201384.","journal-title":"N Engl J Med"},{"issue":"24","key":"2700_CR43","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"2700_CR44","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346.","journal-title":"N Engl J Med"},{"issue":"2","key":"2700_CR45","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"23","key":"2700_CR46","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329.","journal-title":"N Engl J Med"},{"issue":"11","key":"2700_CR47","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P, et al. Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail. 2022;10(11):860\u201370.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2700_CR48","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"10278","key":"2700_CR49","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971\u201384.","journal-title":"Lancet"},{"issue":"14","key":"2700_CR50","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403\u201313.","journal-title":"JAMA"},{"issue":"14","key":"2700_CR51","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414\u201325.","journal-title":"JAMA"},{"issue":"10295","key":"2700_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP, Kaneko S, Lee CJ, Fern\u00e1ndez Land\u00f3 L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143\u201355.","journal-title":"Lancet"},{"issue":"6","key":"2700_CR53","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, P\u00e9rez Manghi FC, Fern\u00e1ndez Land\u00f3 L, Bergman BK, et al. Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503\u201315.","journal-title":"N Engl J Med"},{"issue":"10300","key":"2700_CR54","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, Frias JP, Fern\u00e1ndez Land\u00f3 L, Brown K, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021;398(10300):583\u201398.","journal-title":"Lancet"},{"issue":"10313","key":"2700_CR55","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021;398(10313):1811\u201324.","journal-title":"Lancet"},{"issue":"6","key":"2700_CR56","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P, Huh R, Bray R, Patel H, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534\u201345.","journal-title":"JAMA"},{"issue":"3","key":"2700_CR57","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"issue":"10","key":"2700_CR58","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMoa2410819","volume":"392","author":"AM Jastreboff","year":"2025","unstructured":"Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JP, Perreault L, Zhang S, Battula R, Bunck MC. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958\u201371.","journal-title":"N Engl J Med"},{"key":"2700_CR59","unstructured":"Lilly\u2019s Zepbound\u00ae (tirzepatide) superior to Wegovy\u00ae (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% [press release]. 2024."},{"issue":"16","key":"2700_CR60","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","volume":"390","author":"J Butler","year":"2024","unstructured":"Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after acute myocardial infarction. N Engl J Med. 2024;390(16):1455\u201366.","journal-title":"N Engl J Med"},{"issue":"15","key":"2700_CR61","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","volume":"390","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024;390(15):1394\u2013407.","journal-title":"N Engl J Med"},{"issue":"5","key":"2700_CR62","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, Ge J, Weerakkody GJ, Ou Y, Bunck MC, Hurt KC. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025;392(5):427\u201337.","journal-title":"N Engl J Med"},{"issue":"16","key":"2700_CR63","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"2700_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"13","key":"2700_CR65","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa2404881","volume":"391","author":"A Malhotra","year":"2024","unstructured":"Malhotra A, Grunstein RR, Fietze I, Weaver TE, Redline S, Azarbarzin A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193\u2013205.","journal-title":"N Engl J Med"},{"key":"2700_CR66","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-016-0357-x","volume":"15","author":"O Schnell","year":"2016","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 1st cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2016;15:33.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR67","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12933-017-0508-8","volume":"16","author":"O Schnell","year":"2017","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Skra J, et al. Report from the 2nd cardiovascular outcome trial (CVOT) summit of the diabetes and cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2017;16(1):35.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-018-0667-2","volume":"17","author":"O Schnell","year":"2018","unstructured":"Schnell O, Standl E, Catrinoiu D, Genovese S, Lalic N, Lalic K, et al. Report from the 3rd cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2018;17(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR69","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12933-019-0822-4","volume":"18","author":"O Schnell","year":"2019","unstructured":"Schnell O, Standl E, Catrinoiu D, Itzhak B, Lalic N, Rahelic D, et al. Report from the 4th cardiovascular outcome trial (CVOT) summit of the diabetes & cardiovascular disease (D&CVD) EASD study group. Cardiovasc Diabetol. 2019;18(1):30.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR70","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12933-020-01022-7","volume":"19","author":"O Schnell","year":"2020","unstructured":"Schnell O, Standl E, Cos X, Heerspink HJ, Itzhak B, Lalic N, et al. Report from the 5th cardiovascular outcome trial (CVOT) summit. Cardiovasc Diabetol. 2020;19(1):47.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR71","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12933-021-01254-1","volume":"20","author":"O Schnell","year":"2021","unstructured":"Schnell O, Cos X, Cosentino F, Forst T, Giorgino F, Heersprink HJL, et al. Report from the CVOT summit 2020: new cardiovascular and renal outcomes. Cardiovasc Diabetol. 2021;20(1):75.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR72","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12933-022-01481-0","volume":"21","author":"O Schnell","year":"2022","unstructured":"Schnell O, Battelino T, Bergenstal R, Bl\u00fcher M, B\u00f6hm M, Brosius F, et al. Report from the CVOT summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovasc Diabetol. 2022;21(1):50.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-023-01788-6","volume":"22","author":"O Schnell","year":"2023","unstructured":"Schnell O, Battelino T, Bergenstal R, Birkenfeld AL, Ceriello A, Cheng A, et al. CVOT summit 2022 report: new cardiovascular, kidney, and glycemic outcomes. Cardiovasc Diabetol. 2023;22(1):59.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2700_CR74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12933-024-02180-8","volume":"23","author":"O Schnell","year":"2024","unstructured":"Schnell O, Barnard-Kelly K, Battelino T, Ceriello A, Larsson HE, Fern\u00e1ndez-Fern\u00e1ndez B, et al. CVOT summit report 2023: new cardiovascular, kidney, and metabolic outcomes. Cardiovasc Diabetol. 2024;23(1):104.","journal-title":"Cardiovasc Diabetol"},{"key":"2700_CR75","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511973420","volume-title":"Negative binomial regression","author":"JM Hilbe","year":"2011","unstructured":"Hilbe JM. Negative binomial regression. 2nd ed. Cambridge: Cambridge University Press; 2011.","edition":"2"},{"issue":"2","key":"2700_CR76","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1093\/eurheartj\/ehr352","volume":"33","author":"SJ Pocock","year":"2011","unstructured":"Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2011;33(2):176\u201382.","journal-title":"Eur Heart J"},{"issue":"4","key":"2700_CR77","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/1467-9868.00259","volume":"62","author":"DY Lin","year":"2002","unstructured":"Lin DY, Wei LJ, Yang I, Ying Z. Semiparametric regression for the mean and rate functions of recurrent events. J R Stat Soc Ser B Stat Methodol. 2002;62(4):711\u201330.","journal-title":"J R Stat Soc Ser B Stat Methodol"},{"issue":"4","key":"2700_CR78","first-page":"125","volume":"21","author":"MH Murad","year":"2016","unstructured":"Murad MH, Asi N, Alsawas M, Alahdab F. New evidence pyramid. Evid Med. 2016;21(4):125\u20137.","journal-title":"Evid Med"},{"issue":"10","key":"2700_CR79","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1038\/s41591-023-02502-5","volume":"29","author":"DK Tobias","year":"2023","unstructured":"Tobias DK, Merino J, Ahmad A, Aiken C, Benham JL, Bodhini D, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. Nat Med. 2023;29(10):2438\u201357.","journal-title":"Nat Med"},{"key":"2700_CR80","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111666","volume":"211","author":"JR Gavin","year":"2024","unstructured":"Gavin JR, Rodbard HW, Battelino T, Brosius F, Ceriello A, Cosentino F, et al. Disparities in prevalence and treatment of diabetes, cardiovascular and chronic kidney diseases\u2014recommendations from the taskforce of the guideline workshop. Diabetes Res Clin Pract. 2024;211: 111666.","journal-title":"Diabetes Res Clin Pract"},{"issue":"8","key":"2700_CR81","doi-asserted-by":"publisher","DOI":"10.1111\/dme.15332","volume":"41","author":"K Barnard-Kelly","year":"2024","unstructured":"Barnard-Kelly K, Marrero D, de Wit M, Pouwer F, Khunti K, Hermans N, et al. Towards the standardisation of adult person-reported outcome domains in diabetes research: a consensus statement development panel. Diabetic Med J Br Diabetic Assoc. 2024;41(8): e15332.","journal-title":"Diabetic Med J Br Diabetic Assoc"},{"key":"2700_CR82","doi-asserted-by":"crossref","unstructured":"Group. KDIGOKCW. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024; 105(4s): S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"2700_CR83","doi-asserted-by":"crossref","unstructured":"(EASO). EAftSotLEEAftSoDEEAftSoO. EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81(3): 492\u2013542.","DOI":"10.1016\/j.jhep.2024.04.031"},{"issue":"37","key":"2700_CR84","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"key":"2700_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102614","volume":"72","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, Correa-Rotter R, Eckardt KU, Kanda E, Karasik A, Li G, et al. Projecting the clinical burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72: 102614.","journal-title":"EClinicalMedicine"},{"issue":"Suppl 2","key":"2700_CR86","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ckj\/sfae296","volume":"17","author":"D Abasheva","year":"2024","unstructured":"Abasheva D, Ortiz A, Fernandez-Fernandez B. GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity. Clin Kidney J. 2024;17(Suppl 2):19\u201335.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2700_CR87","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/cvr\/cvac027","volume":"119","author":"WW Parksook","year":"2022","unstructured":"Parksook WW, Williams GH. Aldosterone and cardiovascular diseases. Cardiovasc Res. 2022;119(1):28\u201344.","journal-title":"Cardiovasc Res"},{"issue":"10424","key":"2700_CR88","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","volume":"403","author":"KR Tuttle","year":"2024","unstructured":"Tuttle KR, Hauske SJ, Canziani ME, Caramori ML, Cherney D, Cronin L, et al. Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial. Lancet. 2024;403(10424):379\u201390.","journal-title":"Lancet"},{"issue":"11","key":"2700_CR89","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005288","volume":"11","author":"S Selvaraj","year":"2018","unstructured":"Selvaraj S, Claggett B, Shah SJ, Anand I, Rouleau JL, O\u2019Meara E, et al. Prognostic value of albuminuria and influence of spironolactone in heart failure with preserved ejection fraction. Circ Heart Fail. 2018;11(11): e005288.","journal-title":"Circ Heart Fail"},{"issue":"5","key":"2700_CR90","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W, Pater M, Isaacsohn J, Pearce C, et al. Phase 2 trial of Baxdrostat for treatment-resistant hypertension. N Engl J Med. 2023;388(5):395\u2013405.","journal-title":"N Engl J Med"},{"issue":"20","key":"2700_CR91","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148(20):1606\u201335.","journal-title":"Circulation"},{"key":"2700_CR92","unstructured":"(WHO) WHO. Cardiovascular diseases (CVDs) 2021 [Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-%28cvds%29."},{"issue":"20","key":"2700_CR93","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1056\/NEJMra2030281","volume":"385","author":"S Rajagopalan","year":"2021","unstructured":"Rajagopalan S, Landrigan PJ. Pollution and the heart. N Engl J Med. 2021;385(20):1881\u201392.","journal-title":"N Engl J Med"},{"key":"2700_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2022.107662","volume":"171","author":"X Zhu","year":"2023","unstructured":"Zhu X, Wang C, Duan X, Liang B, Genbo XuE, Huang Z. Micro- and nanoplastics: a new cardiovascular risk factor? Environ Int. 2023;171: 107662.","journal-title":"Environ Int"},{"key":"2700_CR95","doi-asserted-by":"crossref","unstructured":"Microplastics are everywhere\u2014we need to understand how they affect human health. Nat Med 2024; 30(4): 913.","DOI":"10.1038\/s41591-024-02968-x"},{"issue":"10","key":"2700_CR96","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1056\/NEJMoa2309822","volume":"390","author":"R Marfella","year":"2024","unstructured":"Marfella R, Prattichizzo F, Sardu C, Fulgenzi G, Graciotti L, Spadoni T, et al. Microplastics and nanoplastics in atheromas and cardiovascular events. N Engl J Med. 2024;390(10):900\u201310.","journal-title":"N Engl J Med"},{"key":"2700_CR97","doi-asserted-by":"crossref","unstructured":"The Lancet Diabetes E. Diabetes education: the key to a brighter tomorrow. Lancet Diabet Endocrinol. 2022; 10(12): 827.","DOI":"10.1016\/S2213-8587(22)00323-0"},{"key":"2700_CR98","unstructured":"Committee ADAPP. American diabetes association\u2014standards of care 2024. Diabetes Care. 2024; 47: S1\u2013S313."},{"key":"2700_CR99","unstructured":"Network GBoDC. Global burden of disease study 2021. Results. Institute for health metrics and evaluation. 2024 [Available from: https:\/\/vizhub.healthdata.org\/gbd-results\/."},{"key":"2700_CR100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.737964","volume":"12","author":"LM Quinn","year":"2021","unstructured":"Quinn LM, Wong FS, Narendran P. Environmental determinants of type 1 diabetes: from association to proving causality. Front Immunol. 2021;12: 737964.","journal-title":"Front Immunol"},{"issue":"6","key":"2700_CR101","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41574-023-00837-0","volume":"19","author":"D Tatovic","year":"2023","unstructured":"Tatovic D, Narendran P, Dayan CM. A perspective on treating type 1 diabetes mellitus before insulin is needed. Nat Rev Endocrinol. 2023;19(6):361\u201370.","journal-title":"Nat Rev Endocrinol"},{"issue":"8","key":"2700_CR102","first-page":"1276","volume":"47","author":"M Phillip","year":"2024","unstructured":"Phillip M, Achenbach P, Addala A, Albanese-O\u2019Neill A, Battelino T, Bell KJ, et al. Consensus guidance for monitoring individuals with islet autoantibody-positive pre-stage 3 type 1 diabetes. Diabetes Care. 2024;47(8):1276\u201398.","journal-title":"Diabetes Care"},{"issue":"23","key":"2700_CR103","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1056\/NEJMoa2308743","volume":"389","author":"EL Ramos","year":"2023","unstructured":"Ramos EL, Dayan CM, Chatenoud L, Sumnik Z, Simmons KM, Szypowska A, et al. Teplizumab and \u03b2-cell function in newly diagnosed type 1 diabetes. N Engl J Med. 2023;389(23):2151\u201361.","journal-title":"N Engl J Med"},{"issue":"5","key":"2700_CR104","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2337\/dc22-2200","volume":"46","author":"WE Russell","year":"2023","unstructured":"Russell WE, Bundy BN, Anderson MS, Cooney LA, Gitelman SE, Goland RS, et al. Abatacept for delay of type 1 diabetes progression in stage 1 relatives at risk: a randomized, double-masked. Controlled Trial Diabetes Care. 2023;46(5):1005\u201313.","journal-title":"Controlled Trial Diabetes Care"},{"issue":"9","key":"2700_CR105","first-page":"1893","volume":"26","author":"PM Seferovi\u0107","year":"2024","unstructured":"Seferovi\u0107 PM, Paulus WJ, Rosano G, Polovina M, Petrie MC, Jhund PS, et al. Diabetic myocardial disorder. A clinical consensus statement of the heart failure association of the ESC and the ESC working group on myocardial & pericardial diseases. Eur J Heart Fail. 2024;26(9):1893\u2013903.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"2700_CR106","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2337\/db07-0481","volume":"56","author":"S Boudina","year":"2007","unstructured":"Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes. 2007;56(10):2457\u201366.","journal-title":"Diabetes"},{"issue":"17","key":"2700_CR107","doi-asserted-by":"publisher","first-page":"e168563","DOI":"10.1172\/jci.insight.168563","volume":"8","author":"JA Regan","year":"2023","unstructured":"Regan JA, Mentz RJ, Nguyen M, Green JB, Truby LK, Ilkayeva O, Newgard CB, Buse JB, Sourij H, Sj\u00f6str\u00f6m CD, Sattar N. Mitochondrial metabolites predict adverse cardiovascular events in individuals with diabetes. JCI Insight. 2023;8(17):e168563.","journal-title":"JCI Insight"},{"issue":"7","key":"2700_CR108","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/dmrr.1239","volume":"27","author":"V Spallone","year":"2011","unstructured":"Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639\u201353.","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"2700_CR109","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12933-024-02185-3","volume":"23","author":"TME Davis","year":"2024","unstructured":"Davis TME, Tan E, Davis WA. Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle diabetes study phase II. Cardiovasc Diabetol. 2024;23(1):102.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"2700_CR110","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1007\/s00125-024-06242-0","volume":"67","author":"A Eleftheriadou","year":"2024","unstructured":"Eleftheriadou A, Spallone V, Tahrani AA, Alam U. Cardiovascular autonomic neuropathy in diabetes: an update with a focus on management. Diabetologia. 2024;67(12):2611\u201325.","journal-title":"Diabetologia"},{"issue":"5","key":"2700_CR111","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1007\/s00125-024-06107-6","volume":"67","author":"M Jancev","year":"2024","unstructured":"Jancev M, Vissers T, Visseren FLJ, van Bon AC, Sern\u00e9 EH, DeVries JH, et al. Continuous glucose monitoring in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetologia. 2024;67(5):798\u2013810.","journal-title":"Diabetologia"},{"issue":"7","key":"2700_CR112","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41574-024-00973-1","volume":"20","author":"RA Ajjan","year":"2024","unstructured":"Ajjan RA, Battelino T, Cos X, Del Prato S, Philips JC, Meyer L, et al. Continuous glucose monitoring for the routine care of type 2 diabetes mellitus. Nat Rev Endocrinol. 2024;20(7):426\u201340.","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2700_CR113","doi-asserted-by":"publisher","first-page":"441","DOI":"10.2337\/dc22-1219","volume":"46","author":"RA Ajjan","year":"2023","unstructured":"Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter randomized trial of intermittently scanned continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes and recent-onset acute myocardial infarction: results of the LIBERATES trial. Diabetes Care. 2023;46(2):441\u20139.","journal-title":"Diabetes Care"},{"issue":"15","key":"2700_CR114","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","volume":"363","author":"S Zoungas","year":"2010","unstructured":"Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, et al. Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010;363(15):1410\u20138.","journal-title":"N Engl J Med"},{"issue":"9","key":"2700_CR115","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC Jr, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818\u201328.","journal-title":"N Engl J Med"},{"key":"2700_CR116","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000542287","volume":"68","author":"O Moser","year":"2024","unstructured":"Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European association for the study of diabetes (EASD) and the international society for pediatric and adolescent diabetes (ISPAD). Horm Res Paediatr. 2024;68:1\u201328.","journal-title":"Horm Res Paediatr"},{"issue":"2","key":"2700_CR117","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00125-024-06308-z","volume":"68","author":"O Moser","year":"2025","unstructured":"Moser O, Zaharieva DP, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, et al. The use of automated insulin delivery around physical activity and exercise in type 1 diabetes: a position statement of the European association for the study of diabetes (EASD) and the international society for pediatric and adolescent diabetes (ISPAD). Diabetologia. 2025;68(2):255\u201380.","journal-title":"Diabetologia"},{"issue":"7121","key":"2700_CR118","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nature05487","volume":"444","author":"LF Van Gaal","year":"2006","unstructured":"Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444(7121):875\u201380.","journal-title":"Nature"},{"issue":"9","key":"2700_CR119","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41569-022-00679-9","volume":"19","author":"G Iacobellis","year":"2022","unstructured":"Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593\u2013606.","journal-title":"Nat Rev Cardiol"},{"issue":"11\u201312","key":"2700_CR120","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1111\/apt.18331","volume":"60","author":"PN Newsome","year":"2024","unstructured":"Newsome PN, Sanyal AJ, Engebretsen KA, Kliers I, \u00d8stergaard L, Vanni D, et al. Semaglutide 2.4 mg in participants with metabolic dysfunction-associated steatohepatitis: baseline characteristics and design of the phase 3 ESSENCE trial. Aliment Pharmacol Ther. 2024;60(11\u201312):1525\u201333.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"2700_CR121","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299\u2013310.","journal-title":"N Engl J Med"},{"issue":"4","key":"2700_CR122","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, et al. A phase 2 randomized trial of survodutide in MASH and fibrosis. N Engl J Med. 2024;391(4):311\u20139.","journal-title":"N Engl J Med"},{"issue":"9918","key":"2700_CR123","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/S0140-6736(13)60734-5","volume":"383","author":"AS Jordan","year":"2014","unstructured":"Jordan AS, McSharry DG, Malhotra A. Adult obstructive sleep apnoea. Lancet. 2014;383(9918):736\u201347.","journal-title":"Lancet"},{"issue":"2","key":"2700_CR124","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1513\/pats.200708-119MG","volume":"5","author":"TE Weaver","year":"2008","unstructured":"Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173\u20138.","journal-title":"Proc Am Thorac Soc"},{"issue":"8","key":"2700_CR125","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/nu9080913","volume":"9","author":"J de Toro-Mart\u00edn","year":"2017","unstructured":"de Toro-Mart\u00edn J, Arsenault BJ, Despr\u00e9s JP, Vohl MC. Precision nutrition: a review of personalized nutritional approaches for the prevention and management of metabolic syndrome. Nutrients. 2017;9(8):913.","journal-title":"Nutrients"},{"issue":"1","key":"2700_CR126","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cmet.2022.12.002","volume":"35","author":"I Trouwborst","year":"2023","unstructured":"Trouwborst I, Gijbels A, Jardon KM, Siebelink E, Hul GB, Wanders L, et al. Cardiometabolic health improvements upon dietary intervention are driven by tissue-specific insulin resistance phenotype: a precision nutrition trial. Cell Metab. 2023;35(1):71-83.e5.","journal-title":"Cell Metab"},{"issue":"10","key":"2700_CR127","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1111\/dom.14477","volume":"23","author":"DR Quast","year":"2021","unstructured":"Quast DR, Nauck MA, Schenker N, Menge BA, Kapitza C, Meier JJ. Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting glucagon-like peptide-1 receptor agonists in type 2 diabetes. Diabetes Obes Metab. 2021;23(10):2344\u201353.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2700_CR128","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.2337\/dci23-0100","volume":"47","author":"JC Locatelli","year":"2024","unstructured":"Locatelli JC, Costa JG, Haynes A, Naylor LH, Fegan PG, Yeap BB, et al. Incretin-based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition? Diabetes Care. 2024;47(10):1718\u201330.","journal-title":"Diabetes Care"},{"issue":"18","key":"2700_CR129","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","volume":"384","author":"JR Lundgren","year":"2021","unstructured":"Lundgren JR, Janus C, Jensen SBK, Juhl CR, Olsen LM, Christensen RM, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719\u201330.","journal-title":"N Engl J Med"},{"issue":"9","key":"2700_CR130","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1002\/oby.24067","volume":"32","author":"JP Almandoz","year":"2024","unstructured":"Almandoz JP, Wadden TA, Tewksbury C, Apovian CM, Fitch A, Ard JD, et al. Nutritional considerations with antiobesity medications. Obesity. 2024;32(9):1613\u201331.","journal-title":"Obesity"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02700-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T20:02:46Z","timestamp":1746216166000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02700-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":130,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2700"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02700-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"18 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"OS (Oliver Schnell) is the founder and CEO of Sciarc and reports consulting, speaking, or serving on advisory boards for AstraZeneca, Bayer, Boehringer Ingelheim, Lilly, MSD, Mundipharma, Novo Nordisk, Roche, Sanofi, and W\u00f6rwag Pharma. JA (Jaime Almandoz) declares that he has no competing interests. LA (Lisa Anderson) received speaker fees from Vifor, Alnylam, served on advisory boards for Alnylam, Pharmacosmos, received research support from Pfizer and travel and accommodation expenses from Abbott and Roche. KBK (Katharine Barnard-Kelly) is founder and shareholder at Spotlight-AQ Ltd. KBK has received research support from Dexcom, Embecta, JDRF, Novo Nordisk and Roche Diabetes Care, and honoraria from Sanofi. TB (Tadej Battelino) has served on the advisory boards of Abbott, Boehringer Ingelheim, Dreamed Diabetes, Eli Lilly and Company, Indigo Diabetes, Medtronic, Novo Nordisk, and Sanofi. TB has received speaker\u2019s bureau honoraria from Abbott, Eli Lilly and Company, Medtronic, Novo Nordisk, Roche, and Sanofi. The University Medical Center has received research grant support from Abbott, GluSense, Medtronic, Novo Nordisk, Sandoz, Sanofi, and Zealand Pharma. MB (Matthias Bl\u00fcher) received honoraria as a consultant and speaker from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, Lilly, Novo Nordisk, Novartis, and Sanofi. LB (Luca Busetto) declares that he has no competing interests. DC (Doina Catrinou) declares that she has no competing interests. AC (Antonio Ceriello) disclosed the following conflict of interest: Advisory Board, Consultancy, Lectures: Abbott, Bayer, Berlin Chemie, Boehringer Ingelheim, Hikamr Pharma, Guidotti, Eli Lilly, MSD, Merck, Novo, Roche Diagnostics, Sanofi, Servier, SUN Pharma. XC (Xavier Cos) declares that he has no competing interests. TD (Thomas Danne) declares that he has no competing interests. CMD (Colin M. Dayan) declares that he has no competing interests. SDP (Stefano Del Prato) served as president of the European Association for the Study of Diabetes (EASD)\/European Foundation for the Study of Diabetes (EFSD) from 2020 to 2022; Is currently President of Fondazione Menarini; has served as an advisor for Abbott, Amarin Corporation, Amplitude, Applied Therapeutics, AstraZeneca, Biomea Fusion, Eli Lilly & Co., EvaPharma, Menarini International, Novo Nordisk, Sanofi, and Sun Pharmaceuticals; and has received fees for speaking from AstraZeneca, Berlin-Chemie, Boehringer Ingelheim, Eli Lilly & Co., Laboratori Guidotti, Menarini International, Novo Nordisk, and Sanofi. BFF (Beatriz Fern\u00e1ndez-Fern\u00e1ndez) has received grants from AstraZeneca and Esteve and consultancy or speaker fees or travel support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Menarini, Novo Nordisk, and Mundipharma.TF (Thomas Forst) has been a member of the speaker panel of Amarin, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Cipla, Daiichi-Sankyo, Eli Lilly and Company, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, Santis, and of the advisory panel of Atrogi, Bayer, Cipla, Diabetes-Akademie Bad Mergentheim e.V., Eli Lilly and Company, Eyesense, Fortbildungskolleg, Novo Nordisk, Pfizer, reMYND, Roche and Sanofi. PF (Paola Fioretto) has received fees as consultant and speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly company and Novo Nordisk. TF (Thomas Forst) is an employee of CRS Clinical Research Services GmbH, Germany and has contributed to speaker panels for Amarin, AstraZeneca, Boehringer Ingelheim, Berlin Chemie, Cipla, Daiichi-Sankyo, Eli Lilly and Company, Fortbildungskolleg, MSD, Novartis, Novo Nordisk, Sanofi, and Santis and advisory panels for AstraZeneca, Atrogi, Bayer, Cipla, Diabetes Akademie Bad Mergentheim, Eli Lilly and Company, Eysense, Fortbildungskolleg, Novo Nordisk, Pfizer, Sanofi, Remynd, and Roche. JRG (James R. Gavin III) has served on the advisory boards of Abbott Diabetes Care and Embecta, and on the speaker\u2019s bureaus of Boehringer Ingelheim and Eli Lilly and Company. FG (Francesco Giorgino) has served on Advisory Boards: AstraZeneca, Biomea, Boehringer-Ingelheim, Eli Lilly, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi; Other Boards: Senior Vice-President of the European Association for the Study of Diabetes (EASD)\/European Foundation for the Study of Diabetes (EFSD); Consultant: Eli Lilly, NovoNordisk, Biomea; Lectures, presentations, or educational events: AstraZeneca, Boehringer-Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Medtronic, NovoNordisk, Roche Diabetes Care, Sanofi; Research Support: Eli Lilly, Roche Diabetes Care; Receipt of Medical Writing or Support for Statistical Analysis: AstraZeneca, Eli Lilly, NovoNordisk, Roche Diabetes Care, Sanofi. PHG (Per-Henrik Groop) has received lecture honoraria from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Berlin Chemie, Eli Lilly and Company, EloWater, Genzyme, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, Peer Voice, Sanofi and Sciarc. PHG also serves as an advisory board member for AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly and Company, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. IAH (Igor A. Harsch) has received speaker and\/or consultancy fees from Bristol Myers Squibb, Almirall, Boehringer Ingelheim, Lilly Deutschland GmbH, NOVO Nordisk, and AbbVie. HJLH (Hiddo J.L. Heerspink) declares that he has no competing interests. LH (Lutz Heinemann) declares that he has no competing interests. MI (Mahmoud Ibrahim) has consultancy agreement with and received speaker honoraria from Boehringer Ingelheim, Medtronic, Novo Nordisk, and Pfizer. MJ (Michel Jadoul) has received speaker and\/or consultancy fees from Astellas, Astra-Zeneca, Bayer, Boehringer-Ingelheim,Cardiorenal, CSL Vifor, GSK, Novo Nordisk, Menarini, Stada-EG and Vertex. He is since januari 2019 cochair of Kidney Disease: Improving Global Outcomes (KDIGO). SJ (Sarah Jarvis) declares that she has no competing interests. LJ (Linong Ji) declares that he has no competing interests. NK (Naresh Kanumilli) declares that he has no competing interests. MK (Mikhail Kosiborod) reports consulting or advisory board participation for 35Pharma, Alnylam Pharmaceuticals, Amgen, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Dexcom, Eli Lilly and Company, Esperion Therapeutics, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Merck (Diabetes and Cardiovascular), Novo Nordisk, Pharmacosmos, Pfizer, scPharmaceuticals, Sanofi, Structure Therapeutics, Vifor Pharma and Youngene Therapeutics. MK has also received honoraria from AstraZeneca, Boehringer Ingelheim and Novo Nordisk, and research grants from AstraZeneca, Boehringer Ingelheim and Pfizer. UL (Ulf Landmesser) declares that he has no competing interests. SM (Sofia Macieira) is an employee of Sciarc. BM (Boris Mankovsky) has served on advisory boards and received speaking fees from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi, Servier, and W\u00f6rwag Pharma. NM (Nikolaus Marx) has received research grants from Boehringer Ingelheim and MSD, speaking fees form Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Eli Lilly and Company, MSD, Novo Nordisk, and Sanofi-Aventis and has served or serves on the advisory board of Amgen, Bayer, BMS, Boehringer Ingelheim, MSD, Novo Nordisk, and Sanofi-Aventis. CM (Chantal Mathieu) serves or has served on the advisory panel for ActoBio Therapeutics, Avotres, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Imcyse, Insulet, Mannkind, Medtronic, Merck Sharp and Dohme Ltd., Novartis, Novo Nordisk, Pfizer, Sandoz, Sanofi, Roche, Vertex and Zealand Pharma. CM serves or has served on the speakers\u2019 bureau for AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Novartis Novo Nordisk, and Sanofi. Financial compensation for these activities has been received by KU Leuven. KU Leuven has received research support for CM from ActoBio Therapeutics, Imcyse, Medtronic, Novo Nordisk, and Sanofi. BM (Barbara McGowan) has received grant\/research supports and\/or honoraria\/consultation fees by Novo Nordisk, Lilly, Boehringer Ingelheim, and Astrazeneca. BM has received speaker\u2019s bureau honoraria from Novo Nordisk, Lilly, and Amgen. TM (Tatjana Milenkovic) declares that she has no competing interests. OM (Othmar Moser) declares that he has no competing interests. DMW (Dirk M\u00fcller-Wieland) participates in advisory boards and has served on the speaker bureau for Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, GlaxoSmithKline, Novartis, Novo Nordisk, and Sanofi. NP (Nikolaos Papanas) declares that he has no competing interests. DCP (Dipesh C. Patel) has served on advisory panels for AstraZeneca, Boehringer Ingelheim, Eli Lilly, and Sanofi and was involved in educational work for Astra Zeneca, Eli Lilly, Novo Nordisk. AP (Andreas Pfeiffer) declares that he has no competing interests. DR (Dario Raheli\u010b) declares that he has no competing interests. HWR (Helena W. Rodbard) has served on advisory boards for Bayer, Dexcom, Endogenex, Kriya, and Pacira. She has received research support from Eli Lilly, Invesago, Medtronic, Novo Nordisk, and Sanofi. She has participated in Speakers Bureau for Eli Lilly. LR (Lars Ryd\u00e9n) declares that he has no competing interests. ES (Elke Schaeffner) has received honorarium from the National Kidney Foundation for international editorship for the American Journal of Kidney Diseases, from AstraZeneca for consulting and Amgen for session moderation. She was member of the KDIGO working group for the 2024 guideline on CKD evaluation and management. WS (Wendy Spearman) declares that she has no competing interests. AS (Alin Stirban) declares that he has no competing interests. FT (Frank Tacke) declares that work in his lab has been supported by research grants from AstraZeneca, Gilead, and MSD. F. T. has received honoraria for consulting or lectures from AstraZeneca, Gilead, AbbVie, BMS, Boehringer, Madrigal, Falk, MSD, GSK, Pfizer, Novo Nordisk, Sanofi, and Novartis. PT (Pinar Topsever) has received honoraria or consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and LifeScan, and has served on the speaker\u2019s bureau for AstraZeneca. PT received grant\/research support from PCDE, made possible by corporate sponsorship from AstraZeneca, Eli Lilly, Novo Nordisk, and Roche Diagnostics; the sponsors had no input into the study protocols. LVG (Luc van Gaal) declares that he has no competing interests. ES (Eberhard Standl) reported personal fees from Oxford Diabetes Trials Unit, Bayer, Berlin Chemie, Boehringer Ingelheim, Merck, Novartis, and Novo Nordisk.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}